drugset / Trial / NCT05655507
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
Timeline
- Start
- 2023-04-19
- Primary completion
- 2024-10-18
- Completion
- 2024-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zuranolone | Small molecule | 40 mg | Oral |
| Subject | Zuranolone | Small molecule | 50 mg | Oral |